Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.

The British journal of surgery - 1 Nov 2012

Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, Wrba F, Gruenberger T

Abstract excerpt

BACKGROUND: The prognostic value of KRAS mutation in patients with colorectal cancer liver metastases (CLM) receiving neoadjuvant chemotherapy including bevacizumab before liver resection is unclear. METHODS: The KRAS and BRAF status of resected CLM was assessed in prospectively studied patients. Mutations were correlated with recurrence-free and overall survival. Only patients with remaining vital tumour cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Chemotherapy, Adjuvant

Share to Genes, ras

Share to Liver Neoplasms

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 23027075
DOI: 10.1002/bjs.8909

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.PMID 23027075Read ↗

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab (Br J Surg 2012; 99: 1575-1582).Semantic proximity Read ↗

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.Semantic proximity Read ↗

Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.Semantic proximity Read ↗

Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.Semantic proximity Read ↗

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.Semantic proximity Read ↗

RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.Semantic proximity Read ↗

Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases.Semantic proximity Read ↗

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.Semantic proximity Read ↗

KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.Semantic proximity Read ↗

Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.Semantic proximity Read ↗

From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.